Testpage/Main 1: Difference between revisions
< Testpage
Jacki Buros (talk | contribs) No edit summary |
Jacki Buros (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
:The ATLAS ACS-TIMI 46 Study Group investigators reported today in ''The Lancet'' that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51). | :The ATLAS ACS-TIMI 46 Study Group investigators reported today in ''The Lancet'' that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51). | ||
{{#tag:googleNewsDynamic|newstitle=Today in Medicine|sites=wsj.com:nytimes.com:geekdoctor.blogspot.com|numresults=10}} | {{#tag:googleNewsDynamic|newstitle=Today in Medicine|sites=wsj.com:nytimes.com:geekdoctor.blogspot.com:news-medical.net|numresults=10}} | ||
|- | |- | ||
|} | |} | ||
Latest revision as of 14:33, 2 July 2009
|